Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
A (Dog’s) Day in the Life: Work from Home Edition
My name is Denali. I’m one of the regular Doggie Day “coworkers” at UPMC Enterprises. However, it has been a couple months since my mom started working from home full-time.
Read More →
Meet the Executive: David Gibson, Chief Financial Officer of UPMC Enterprises
David Gibson was named Chief Financial Officer of UPMC Enterprises in November 2019. As CFO, …
Read More →